Breast cancer patients and their families might hold the important key to enabling new technologies that can help pinpoint the right treatment for the right patient at the right time. A new genomics project spearheaded by Santa Clara-based Iris BioTechnologies is looking for participants to offer information that will lead to more personalized medicine for the treatment of breast cancer and other deadly illnesses.

With widely different responses to the more than thirty chemotherapeutic agents in use today the ability to rapidly classify "generic" diseases like breast cancer into genetic subtypes is long overdue. In the past, oncologists have made treatment decisions based solely upon broadly defined disease knowledge and personal experience, with little or no insight into the molecular biology of cancer. Thanks to advances in technology the necessary clinical tools are rapidly becoming available.

One new tool is the Iris Breast Cancer Chip, which captures crucial molecular information concerning the activity of more than one hundred genes implicated in the disease from a breast biopsy sample. When processed, this information creates an optical pattern that is then analyzed by the company's proprietary data program called "BioWindows," which launched earlier this year.

"By combining the patient's cancer gene profile with their environmental, hereditary and lifestyle information, doctors can pinpoint what drugs worked for patients with similar profiles," explains Simon Chin, CEO of Iris. "The marriage of these two technologies is essential to assist doctors with practical prognosis, disease prevention, and the development of more fully targeted medicine."

Iris expects to launch their first Nano-Biochip to identify gene expression patterns in breast cancer later this year. For now, breast cancer patients and their families are welcome to enter information into the database at www.biowindows.com.

"Looking at a mirror offers a sense of what you look like on the outside; with the Nano-Biochip and BioWindows technology you have a glimpse of the 'inner you' based upon heredity and factors that impact your genes," says Mr. Chin. "We believe the future of treatment is in personalized medicine, and it all starts with your involvement."